neuropharmacology Flashcards
3 main MOAs of anti-epileptic drugs (+ examples)
- Na+ Ch block -> inhibit APs -> stabilise Na+ Chs => reduce frequency of discharge (e.g. lamotrigine, phenytoin, carbamezepine);
- enhance GABA transmission (e.g. benzodiazepam - ↑GABA, sodium valporate -↓ GABA-T => ↓ GABA reuptake);
- reduce glutamate release (e.g. lamotrigine)
examples of side effects of Lamotrigine (5)
- skin reactions;
- blood disorders;
- headaches;
- drowsiness/dizziness;
- osteoporosis
(5. interacts w valporate)
why should sodium valporate not be given to women
it is tetragenic
what should be done if the first line agent doesn’t work (epilepsy)
titrate up 2nd agent while gradually withdrawing the first -> shouldn’t leave them with no treatment at all
when can epilepsy treatment begin to be stopped
if 2 years seizure free
concerns for pregnant epileptic pts (foetal development)
drugs are all tatragenic -> neural tube defects, cranial facial defects
what should be done for pregnant epileptic pts (pharma wise -2)
- aim for a single drug at the lowest possible dose to prevent seizures that could result in hypoxia;
- folic acid supplements
why can a MAX of 2 doses only be given in status epilepticus
can cause respiratory depression
4 parts to parkinson’s mgx (pharma)
- give DA precursor (L-DOPA)
- give DA agonoist (bromocriptine, cabergoline etc.)
- reduce endogenous DA breakdown anzymes (i.e. MOA-Bi e.g. selegilin)
- release DA from stores + inhibit reuptake (e.g. amantadine)
why is levodopa usually given alongside other drugs (2)
reduces its side effects (reduce binding in the periphery); reduces the amount needed to be effective (stops binding at unintended sites)
side effects of levodopa
chorea, atonia, nausea, postural hypotension
carbidopa and benserazide MOA
dopamine decarboxylase inhibitors -> stops levodopa being metabolised in the periphery => side effects are reduced and lower levodopa dose needed as more reaches the target organ;
can’t cross BBB so has o effect on the CNS
selegiline/rasagiline MOA
inhibits the MAO-B pathway => increase in DA travelling to intended site
tolcapone MOA
inhibtis COMT pathway => increase in DA travelling to intended site
why is L-DOPA used in PD rather than DA itself (3)
- DA has poor oral absorption;
- DA cant cross BBB;